UPDATED: FEBRUARY 3, 2014

CURRICULUM VITAE
Steven L. Mansberger, M.D., M.P.H.
Vice-Chair, Devers Eye Institute
Director of Glaucoma Services and Fellowship Program, Devers Eye Institute
Senior Scientist, Legacy Health
Chair, Continuing Medical Education Committee, Legacy Health
Clinical Associate Professor of Ophthalmology, Casey Eye Institute at OHSU
Clinical Associate Professor, Dept of Public Health and Preventive Medicine at OHSU
President, Oregon Academy of Ophthalmology

Devers Eye Institute at Legacy Health

1040 NW 22nd Ave, Suite 200
Portland, OR 97210
Phone: 503-413-8202
[email protected]

Education
July 1987-May 1991 Miami University of Ohio, Oxford, OH.
B.A, Zoology
July 1991-May 1995 Indiana University School of Medicine; Indianapolis, IN.
Doctor of Medicine
September 2000-June 2002 Oregon Health Science University (OHSU)
Portland, OR
Masters of Public Health (MPH)
(Biostatistics/Epidemiology)

June 2004-2005 Oregon Health Science University

Human Investigations Program
(Clinical Research track)

Professional Experience
July 1995-June 1996 Internal Medicine, St. Vincent Hospital, Portland, Oregon.
July 1996-June 1999 Ophthalmology residency, Shiley Eye Center, University of
California, San Diego.
July 1999-June 2000 Glaucoma Fellowship, Devers Eye Institute, Good Samaritan
Hospital. Portland, OR.
July 2000-2006 Assistant Scientist
Devers Eye Institute/Legacy Health System, Portland, OR

July 2000-Present Head of Ophthalmic Clinical Trials, Devers Eye

Institute/Legacy Health System, Portland, OR
July 2000-2008 Adjunct Assistant Professor of Ophthalmology, Oregon
Health Science University, Portland, OR
July 2000-2009 Director Glaucoma Service, Veteran‟s Hospital, Portland, OR

1
 June 2002-July 2004 Medical Director, Devers Memorial Eye Clinic, Portland, OR
January 2004-Present Clinical Assistant Professor of Public Health and Preventive
Medicine, Oregon Health Science University

November 2006-Present Associate Scientist, Legacy Health System

November 2008-Present Affiliate Associate Professor, Oregon Health Science

University

June 2009-2012 Co-Medical Director, Telemedicine Services, Legacy Health

System

July 2009-Present Director of Glaucoma Services, Devers Eye Institute

July 2009-Present Director of Glaucoma Fellowship, Devers Eye Institute

March 2012-Present Senior Scientist, Legacy Health

September 2012-Present Vice-Chair, Devers Eye Institute

Research Training
Wilmer Eye Institute, Eye Pathology Laboratory; Johns Hopkins University, Baltimore, Maryland,
October 1994-November 1994.
-Pathologic examination of ocular specimens
Research Director: W. Richard Green, M.D.

Indiana University Glaucoma Research and Diagnostic Lab; Indianapolis, Indiana, May 1992-
June 1995.
-Examining blood flow using the Scanning Laser Ophthalmoscope, Blue Field Simulator, and Color
Doppler Imaging
Research Director: Alon Harris, Ph.D.

Devers Eye Institute, Portland, Oregon, January 1994-February 1994.

-Investigating retrobulbar vessel anatomy using plastic dye casting and electron microscopy
Research Director: George A. Cioffi, M.D.

Glaucoma Center and Research Laboratories, University of California, San Diego; San Diego, CA.
January 1997-June 1999
-Functional testing of glaucoma including achromatic automated perimetry and short wavelength
perimetry.
-Structural analysis of the optic nerve with confocal scanning laser ophthalmoscopy
-Circadian rhythm of intraocular pressure in the young and elderly subjects
Research Director: Robert N. Weinreb, M.D., John Liu, PhD

Devers Eye Institute/Discoveries in Sight; Portland, OR. July 1999-present

-Functional testing of glaucoma including achromatic automated perimetry and frequency doubling
technology perimetry.
-Structural analysis of the optic nerve with confocal scanning laser ophthalmoscopy
-Community screening of glaucoma with frequency doubling technology perimetry

2
 -Prevalence of eye diseases in American Indian/Alaskan Natives
-Predictive ability of nonmydriatic imaging for diabetic retinopathy
Research Director: George A. Cioffi, M.D., Chris A. Johnson, PhD

Honors and Awards

1. Mid-American Conference, All-Academic team-Soccer, 3rd team 1987
2. Mid-American Conference, All-Academic team-Soccer, 2nd team 1988.
3. Cum Laude, Miami University of Ohio, May 1991.
4. Poster Presentation, Third place, Indiana State Medical Association, Indianapolis, IN, 1994.
5. Poster presentation, Third Place, Midwest Student Research Forum, Omaha, NE, 1994.
6. Roche Laboratories Travel Award, National Student Research Forum, Galveston, TX, 1994.
7. Chief Resident, July 1998-June 1999.
8. Outstanding Resident Award, June 1999.
9. Resident Knowledge Award, June 1999.
10. Heed Ophthalmic Foundation Fellowship, July 1999-June 2000.
11. Master‟s Thesis of the Year Nomination, June 2002
12. The Robert Watzke Ophthalmology Instructor of the Year, Casey Eye Institute, Oregon Health
Science University, June 2002
13. American Glaucoma Society Research Fellowship in Glaucoma, March 2003
14. American Glaucoma Society Research Fellowship in Glaucoma, March 2004
15. Scientist of the Month, Legacy Health System, June 2004
16. ASCI/AAP travel award, April 2006
17. Achievement Award, American Academy of Ophthalmology, October 2006
18. Leadership Program, American Academy of Ophthalmology, 2006
19. Best Doctors in America: 2007
20. Oral Board Examiner, American Board of Ophthalmology, 2007 to present
21. Best Doctors in America: 2008
22. Best Doctors in America: 2009
23. Distinguished Alumni Lecturer, Shiley Eye Center, University of California, San Diego. San Diego,
CA. 2010
24. Best Doctors in America: 2010
25. Carmel High School Hall of Fame, Carmel, IN. 2010
26. Best Doctors in America: 2011
27. 3rd Place Poster, Diabetes Translational Research Conference, Minneapolis, MN. 2011
28. Best of the American Glaucoma Society Annual Meeting, Presented at the World Glaucoma
Association meeting, Paris, France. 2011.
29. Best Anterior Segment research presentation, American Academy of Ophthalmology, October 2011.
30. Best Doctors in America, 2012
31. Portland‟s Best Doctors, 2013
32. International Glaucoma Review, Editor‟s choice, 2013. “Reduction in Intraocular pressure after
Cataract Surgery: The Ocular Hypertension Treatment Study”
33. American Ophthalmology Society (AOS), accepted May 2013
34. American Academy of Ophthalmology, State Society Award. November 2013. “Free glaucoma
screenings with your legislator”.
35. Best Doctors in America, 2014

Professional Organizations
Heed Ophthalmology Foundation
o Member 2000-present
American Glaucoma Society
o Provisional Member 2000-2005

3
 o Active Member 2005-present
The Association for Research in Vision and Ophthalmology (ARVO),
o 1993-present
American Academy of Ophthalmology
o Member 1998- present,
o Active Fellow 2001-present
Oregon Academy of Ophthalmology
o 1999-present
World Glaucoma Association
o 2005-present
American Society of Cataract and Refractive Surgery,
o Member 1997- 2002
Eye Care America
o 2000-present
Pan American Academy of Ophthalmology
o 2003-2007
American Ophthalmology Society
o Member 2013- present

Committee Membership/Leadership Positions

Legacy Health System
o Legacy Telemedicine Program
 Co-medical director 2009-2012
 Steering Committee 2009-present
o Continuing Medical Education Committee
 Chair, 2011- present
 Member, 2008-present
o Devers Eye Institute Executive Committee
 Member 2008-present
o Good Samaritan Surgical Services Steering Committee
 Member, 2007-present
o Transitional Care Committee-
 Member, June 2002-July 2004
o Block Time Committee
 Member, 2004-2006
o Ophthalmology Surgery Committee
 Member, 2000-2008
o Graduate Medical Education Committee
 Member, 2008-present
o Legacy Leadership Program
 Member, 2012-2013
Oregon Academy of Ophthalmology
o President, 2012-2014
o Vice President, 2010-2012
o Secretary/Treasurer 2007-2009
o Board of Directors
 Member, 2008-present
American Glaucoma Society
o Board of Directors
 Member, 2010-2013

4
 o Education and Communications Committee
 Chair 2010-2013
 AGS Newsletter Editor 2007-2009
 Member, 2005-2009
o Nominating Committee
 Member, 2011-present
o Strategic Planning Committee
 Member 2008-2010
American Academy of Ophthalmology
o ONE committee-glaucoma
 Member 2005-2009
o BCSC Sec. 1: Update on General Medicine – Consultant for Epidemiology
 2011 to present
o Annual Meeting Program Committee – Glaucoma, Scientific reviewer
 Member, 2012-present
o Preferred Practice Pattern-Glaucoma Panel – Consultant
 Member 2014 to present
o EyeNet Editorial Advisory Board
 Member 2014 to present
Ocular Hypertension Treatment Study (OHTS)
o Executive Committee
 Member 2007-present
World Glaucoma Association
o Associate Advisory Board
 Member, 2008-present
o Poster committee
 Co-chair-2006-2010
o Subcommittee Chair (Clinical Trials, Economics)
 Co-chair 2008-2010
Oregon Health Science University
o Resident Selection Committee
 Member, 2002-2004
Prevent Blindness America
o Scientific advisory board committee 2012-present
Oregon Medical Association
o Institutional Accreditation Committee, 2012-present
Glaucoma Research Foundation
o Scientific Advisory Board, 2013-present

Board Certification
American Board of Ophthalmology, November 2000
Recertification, American Board of Ophthalmology, September 2010

Licensing
California Medical License-April 1997-present
Oregon Medical License-January 2000-present

Executive Editor
1. American Journal of Ophthalmology, Epidemiology section

5
Editorial Boards of Scientific Journals
1. Journal of Glaucoma, 2006 to present
2. American Journal of Ophthalmology, 2006 to present

Scientific Journal Review

1. Journal of Glaucoma, 1999 to present
2. Investigative Ophthalmology and Visual Science, 2000 to present
3. Archives of Ophthalmology, 2000 to present
4. British Journal of Ophthalmology, 2000 to present
5. Survey of Ophthalmology, 2000 to present
6. Ophthalmology, 2003-present
7. American Journal of Ophthalmology, 2002-present
8. Current Eye Research, 2004-present
9. Journal of Cataract and Refractive Surgery, 2005-present
10. Optometry and Visual Science, 2006-present
11. Journal of Ophthalmology, 2009-present
12. PLOS, 2013-present

Corporate Advisory Boards

1. Gehrson-Lehmann-2003 to present
2. Allergan-Glaucoma. 2005 to present
3. Santen-Glaucoma. 2006-present
4. Heidelberg Engineering. 2005-2009
5. Genentech- 2010 to 2011
6. Alcon- 2005-2008, 2012-present
7. Glaukos-2011
8. Merck-2012-present
9. Bausch & Lomb 2013-present
10. Sucampo, 2013-present
11. Valeant Pharmaceuticals, 2013-present
12. Liquidia Technologies, 2013-present

Research Support
Current Research Support
1. National Eye Institute 9/2009-8/2014
R01 EY 019674 Predicting the Rate of Progression in Glaucoma (PI: Demirel, S)
This project will determine predictive factors for progressive glaucomatous change differentiating
between structure of the nerve head, or loss of retinal ganglion cell (RGC) function.
Total Support: $1,950,000
Role: Consultant

2. National Eye Institute 8/2012-8/2016

R01 EY020922 Functional Testing for Glaucoma (PI: Gardiner)
This project will evaluate and improve functional testing for glaucoma.
Total Support: $1,550,230
Role: Consultant

3. Allergan March 2012-March 2014

6
A multicenter, Paired-eye Comparison, Dose-escalation, Single Dose, 24 month Study of Safety and
Efficacy of Bimatoprost Preservative Free Intracameral Delivery System (Bimatoprost PF IC DDS) in
Patients With Open Angle Glaucoma (PI: Mansberger)
Total Support: $231,711
Role: Principal Investigator

4. Mobius Pharmaceuticals March 2013-March 2014

Breakdown products of Mitomycin C (PI: Mansberger)
This project will analyze mitomycin C (a common chemical used in glaucoma surgery) and its breakdown
products using high-pressure liquid chromatography and mass spectrometry.
Total Support: $39,600
Role: Principal Investigator

Previous Research Support:

1. University of Colorado July 2011-June 2013
Motivational interviewing and glaucoma adherence (PI: Mansberger)
This project will compare motivational interviewing vs. usual care in adherence to glaucoma medications.
Total Support: $117,737
Role: Principal Investigator

2. Centers for Disease Control and Prevention (CDC) July 2010-Feb 2013
1U48DP002673 The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy (PI:
Mansberger)
This project will compare telemedicine to current surveillance mechanisms to detect diabetic retinopathy.
Total Support: $ 2,003,926
Role: Principal Investigator

3. AHRQ. January 2011-January 2013

Glaucoma surgery outcomes (PI: Mansberger)
This project will compare trabeculectomy, trabeculoplasty, and additional medications for lowering
intraocular pressure.
Total Support: $45,200
Role: Principal Investigator

4. Allergan 5/2009-5/2010
Horizon Grant (PI: Mansberger)
This grant supports glaucoma fellowship research activities at Devers Eye Institute.
Total Support: $50,000
Role: Principal Investigator

5. Alcon 1/2009-06/2009
Study: Protocol C-08-049 A Dose-Volume of Anecortave Acetate in Patients with Open-Angle Glaucoma
or Ocular Hypertention.
To determine the effect of Anecortave Acetate on intraocular pressure
Total Support: $99,825
Role: Principal Investigator

6. National Eye Institute 7/2000-2009

EY-10362-10 Ocular Hypertensive Treatment Study (PI: Cioffi)

7
The major goals of this project are to determine whether reduction of intraocular pressure with ocular
hypotensive medications prevents or delays the development of glaucoma in ocular hypertensive
patients.
Total Support: $2,470,000
Role: Co-Investigator
7. National Eye Institute July 2004-2009
K23-Northwest Tribal Vision Project (PI: Mansberger)
This is a career development grant to increase Dr. Mansberger‟s skills in epidemiology and biostatistics.
The research project will determine whether ophthalmic technicians using new instruments of testing are
accurate in comparison to an ophthalmologist exam. It also develops preliminary information regarding
the prevalence of eye diseases in Northwest American Indians and Alaskan Natives.
Total Support: $1,170,680
Role: Principal Investigator

8. Centers for Disease Control and Prevention (CDC) October 2004-2009

Tribal Visual Impairment Prevention Program (PI: Mansberger)
The CDC selected Oregon Health Science University as a location for a Health Promotion and Disease
Prevention Research Center. Dr. Mansberger is the principal investigator for the core research project to
compare current surveillance methods to telemedicine with nonmydriatic cameras for detecting diabetic
retinopathy in Alaskan Natives and American Indians. This study will also measure the change in quality
of life with correction of refractive error.
Total Support: $1,075,112
Role: Principal Investigator

9. Allergan July 2006-June 2008

Brimonidine Purite 0.1% TID versus Beta Blocker BID Used as Adjunctive Therapy to Latanoprost
This project determines whether brimonidine or timolol is more affective as an adjunctive treatment to
latanoprost.
Total Support: $75,141
Role: Principal Investigator

10. American Glaucoma Society. October 2005-2006.

Glaucoma Compliance Assessment Tool (PI: Mansberger)
Research into Patient Adherence to Care: The American Glaucoma Society research committee
selected the Glaucoma Compliance Assessment Tool (GCAT) as their first grant for glaucoma
compliance. This study develops a quantitative measure of factors affecting compliance with glaucoma
treatment using the constructs of the Health Belief Model.
Total Support: $55,000
Role: Principal Investigator

11. University of Alabama. January 2006-2007

Risk factors for noncompliance (PI: Mansberger)
This study utilizes a questionnaire to determine the factors associated with compliance with Travatan
Dosing aid.
Total Support: $92,400
Role: Principal Investigator

12. Pfizer 10/2002-2008

Risk Assessment (PI: Mansberger)

8
We monitory the number of eye care providers that access and download our Devers Ocular
Hypertension to Glaucoma Risk Calculator.
Total Support: $74,000
Role: Principal Investigator

13. Legacy Health System 7/2003

RAC grant
This grant supported a nonmydriatic camera for our telemedicine protocol
Total Support: $19,800
Role: Principal Investigator

14. Legacy Health System 7/2003

RAC grant
This grant supported staffing costs for analyzing data from a glaucoma screening in Southern India.
Total Support: $17,591
Role: Principal Investigator

15. Santen 9/2001-12/2001

AFB-168 (PI: Mansberger)
The study will investigate the dose-response relationship of AFP-168 with concentrations of 0.001%,
0.0025%, and 0.005%. It will also compare the safety and efficacy of these three concentrations with
placebo and 0.005% latanoprost.
Total Support: $82,344
Role: Principal Investigator

16. National Eye Institute / SBIR 3/01/02 to 9/01/02

Aqueous Vein Drain Tube (PI Swanson)
The Major Goals of this project are to examine the magnitude of protein and cell binding with various
bioactive coatings and polymers.
Total Support: $43,099
Role: Co-Investigator
17. Allergan 8/2003-8/2004
019T (PI: Mansberger)
This study compares the hypotensive efficacy of 019T (combination of Timolol and Brimonidine) with
individual administration of Timolol and Brimonidine.
Total Support: $84,000
Role: Principal Investigator
18. Collins Foundation 07/1999-08/2003
Screening with Frequency Doubling Technology (FDT) in the Community
This study compares the screening accuracy of FDT for detecting eye diseases and glaucoma in the
community.
Total Support: $800,000
Role: Co-Investigator

19. Allergan 12/2000-6/2007

Memantine (PI: Mansberger)
This randomized control trial examines whether Memantine (an NMDA receptor antagonist) prevents
progressive functional and structural changes from glaucoma.
Total Support: $890,000
Role: Principal Investigator

9
 20. Allergan 1/2006-2008
A multicenter, double-masked, randomized, parallel, active-controlled /three month study (plus 9-month
masked extension) of the safety and efficacy of bimatoprost ophthalmic solution 0.01% and Bimatoprost
Ophthalmic solution 0.0125% once-daily compared with Lumigan (Bimatoprost ophthalmic solution 0.03%
once-daily in patients with glaucoma or ocular hypertension. (PI: Cioffi)
Total Support: $79,000
Role: Co-Investigator

21. American Glaucoma Society. October 2004-2005.

Tribal Vision Project (PI: Mansberger)
This study was a continuation of a funded grant to determine the prevalence of eye diseases in American
Indian/Alaskan Natives.
Total Support: $45,000
Role: Principal Investigator

22. American Glaucoma Society. October 2003-2004.

Tribal Vision Project (PI: Mansberger)
This study was the original grant to determine the prevalence of eye diseases in American
Indian/Alaskan Natives.
Total Support: $45,000
Role: Principal Investigator

23. Alcon Sept 2003-2004

Tribal Vision Project (PI: Mansberger)
This study was a continuation of a funded grant to determine the prevalence of eye diseases in American
Indian/Alaskan Natives.
Total Support: $29,000
Role: Principal Investigator

Invited CME Presentations/lectures (Domestic and International):

1. Grand Rounds, Oregon Health Science University. April 2000. “Screening for glaucoma”
2. Kaiser Regional Conference, Santa Monica, CA. July 2001. Functional Testing of glaucoma for the
clinician” and “Ocular Hypertension”
3. Vision 2000, Portland, OR. September 2001. “Screening for glaucoma using Frequency Doubling
Technology perimetry”
4. Subspecialty Day, American Academy of Ophthalmology. October 2001. “Blebitis: recognition and
treatment”
5. Grand Rounds, Oregon Health Science University. April 2002. “How to practice evidenced-based
ophthalmology”
6. Thorny Issues, Portland, OR. June 2002. “Trabeculectomy Postoperative Management” and
“Evidenced Based Ophthalmology”
7. Ophthalmology Update, Skamania Lodge, Portland, OR. June 2003. “Cataract surgery before
Trabeculectomy”, “Examining the optic disc”, and “Difficult Glaucoma: Case Presentations”
8. OHSU Alumni Meeting, Portland, OR. September 2003. “Postoperative trabeculectomy
management”
9. Bridgeport Glaucoma Society, Portland, OR. October 2003. “Predicting Glaucoma from Ocular
Hypertension: The Glaucoma Risk Calculator”
10. Yale Annual Glaucoma Symposium. October 2003. “Treating the patient not the intraocular
pressure”, “Making the decision to operate”, and “Selective Functional testing for the clinician”

10
11. Alcon Fellows Program, Ft. Worth, TX. November 2003. “Are Glaucoma and Ischemia related? An
evidenced-based approach”
12. Subspecialty Day, American Academy of Ophthalmology. November 2003. “Episcleral Venous
Pressure and Glaucoma”.
13. Ophthalmology Grand Rounds. May 2004. “Treating Ocular hypertension based on Risk: The
Devers Ocular Hypertension to Glaucoma Risk calculator”
14. Thorny Issues, Portland, OR. June 2004. “Glaucoma: A public health crisis?”
15. Medical Grand Rounds, Legacy Health System, Portland, OR. September 2004. “Treating Ocular
hypertension based on Risk: The Devers Ocular Hypertension to Glaucoma Risk calculator”
16. Pan American Academy of Ophthalmology. Santiago, Chili. March 2005. “Selective Functional
Testing of Glaucoma”
17. Pan American Academy of Ophthalmology. Santiago, Chili. March 2005. “Treatment of overfiltration
following glaucoma surgery”
18. Thorny Issues, Portland, OR. June 2005. “Case Presentations in Glaucoma”
19. Optometry Grand Rounds, Veterans Administration Hospital VISN area Northwest. Portland, OR.
July 2005. “Large Clinical Trials in Glaucoma”.
20. Internal Medicine Grand Rounds, Providence Health System. Portland, OR. July 2005.
21. Subspecialty Day, American Academy of Ophthalmology. November 2005. “Recognizing Pre-
perimetric glaucoma”.
22. Vancouver Clinical Day, Vancouver, Canada. January 2006. “Evaluation of the optic disc: HRT,
GdX, OCT, and the 78 dpt lens”, “Risk Calculators for Ocular Hypertension”, “Recognizing
Glaucomatous Progression”, “Prevention Postoperative IOP spikes”, “My trabeculectomy technique”,
“One-eyed trials under fire”.
23. Ophthalmology Grand Rounds, Oregon Health Science University. Portland, Oregon. January 2006.
“Good Blebs gone Bad”
24. World Ophthalmology Congress, Sao Paulo, Brazil. February 2006. “Postoperative Antimetabolites;
How I do it”.
25. Grand Rounds, University of West Virginia, Morgantown, WV. May 2006. “Glaucoma –Risk,
Evaluation, Assessment, and Treatment”.
26. Thorny Issues, Devers Eye Institute, Portland, OR. June 2006. “Lessons from the Ocular
Hypertension Treatment Study.”
27. Improving Your Odds, Ocular Surgery News. Las Vegas, NV. June 2006. “Risk Factors for
Glaucoma.”
28. Optometry Grand Rounds, Veterans Administration Hospital VISN area Northwest.Portland, OR.
September 2006. “Lessons from the OHTS study”.
29. Academy for Healthcare Education, Newark, NJ. September 2006. “Great Expectations: Glaucoma
Risk Evaluation and Treatment.”
30. Academy for Healthcare Education, Honolulu, HI. October 2006. “Great Expectations: Glaucoma
Risk Evaluation and Treatment.”
31. Grand Rounds, Wills Eye Hospital, Philadelphia, PA. October 2006. “Glaucoma –Risk, Evaluation,
Assessment, and Treatment”.
32. American Academy of Ophthalmology, Subspecialty Day. November 2006. “Can you predict which
patients are noncompliant?”
33. Improving Your Odds, American Academy of Ophthalmology. Las Vegas, NV. November 2006.
“Risk assessment in glaucoma: lessons from OHTS and EGPS”
34. Academy for Healthcare Education, Seattle, WA. December 2006. “Great Expectations: Glaucoma
Risk Evaluation and Treatment.”
35. Ski Vision, Snowmass, CO. February 2007. “Determining the risk of blindness from glaucoma”;
“Objective structural testing for glaucoma”; and “Cases in glaucoma”.
36. International Glaucoma Symposium, Singapore. July 2007. “Risk calculators in Glaucoma”, “Target
Intraocular Pressure”, “Risk and Health Economic models”

11
37. Thorny Issues, Portland, OR. September 2007. Neurophthalmology Panel Moderator.
38. Devers/Casey Grand Rounds, Portland, OR. September 2007. “Treating compliance”
39. North American Perimetry Society. September 2007. Skanataelas, NY. “Screening for Breast
Cancer, Prostate Cancer. Why not Glaucoma”
40. VISN Optometry Grand Rounds. November 2007. Portland, Oregon. Improving compliance in
glaucoma patients”.
41. University of Colorado (February 2008). Denver, Colorado. Visiting Professor Grand Rounds.
“Treating your patients, not just the intraocular pressure”.
42. American Glaucoma Society (March 2008). Washington, DC. “Predictive Factors for following up
with an Eye Care Provider”
43. University of Missouri, Kansas City Grand (April 2008). Kansas City, MS. Visiting Professor Grand
Rounds. “Treating noncompliance using the Health Belief Model”
44. Arizona Ophthalmology Society Annual Meeting (May 2008). Sedona, AZ. “Good Blebs Gone Bad”
and “Losing the battle of glaucoma: Signs of glaucomatous progression”
45. American Academy of Ophthalmology, Subspecialty Day. Atlanta, GA. November 2008. “Screening
for glaucoma using perimetry?”
46. American Academy of Ophthalmology. Atlanta, GA. November 2008. “Good blebs gone bad”
47. VISN Optometry Grand Rounds. December 2008. Portland, Oregon. “Lessons from the Ocular
Hypertension Treatment Study.” Improving compliance in glaucoma patients”.
48. Distinguished Alumni Lecture. June 2009. Shiley Eye Center, University of California, San Diego.
San Diego, CA. “Treating the patient, not just the intraocular pressure”
49. American Academy of Ophthalmology. October 2009. San Francisco, CA. “When to needle after
glaucoma surgery”.
50. VISN Optometry Grand Rounds. January 2010. Portland, Oregon. “Case Studies in Glaucoma.”
51. Western Regional Meetings of the American Federation of Medical Research. January 2010.
Carmel, CA. “Telemedicine to detect Diabetic Retinopathy in American Indian/Alaska Natives and
Other Ethnicities”
52. Bascom Palmer Midwinter Forum-Battle on the Beach. January 2010. Miami, FL. “Detection of
glaucomatous optic disc progression” and “Treating the postoperative bleb”.
53. American Telemedicine Association. April 2010. San Antonio, Tx. “Progression of diabetic
retinopathy in American Indian/Alaskan Natives using a telemedicine system”
54. SOPHE-PRC 2010 Joint Conference. April 2010. Atlanta, GA. “Using telemedicine to detect
diabetic retinopathy”
55. World Ophthalmology Congress. June 2010. Berlin, Germany. “Clinical use of risk calculators for
managing glaucoma”
56. Thorny Issues. September 2010. Portland, OR. “Clinical cases in Glaucoma”.
57. American Academy of Ophthalmology, Subspecialty Day. Chicago, IL. October 2010. “Barriers to
Glaucoma Adherence”
58. American Academy of Ophthalmology, Media Day. Chicago, IL. October 2010. “Common eye
problems in American Indians/Alaskan Natives”.
59. American Academy of Ophthalmology, Chicago, IL. October 2010. “Needling revision of
trabeculectomy blebs”.
60. American Academy of Ophthalmology, Editors‟ Choice Awards. Chicago, IL. October 2010.
“Comment: Rates of progressive retinal NFL loss in Glaucoma Measured by Scanning Laser
Polarimetry”.
61. American Academy of Ophthalmology, Chicago, IL. October 2010. “Trabeculectomy Laboratory
Course”
62. Telemedicine Association of Oregon. November 2010. Portland, OR. “Legacy Telehealth and
TeleOphthalmology”

12
63. Berglund Invited Lecturer. Berglund Center for Internet Studies, Pacific University. November 2010.
Portland, OR. “Northwest Tribal Vision Project: Diabetic Eye Disease Detection Non-mydriatic
Retinal Cameras”
64. American Glaucoma Society. March 2011. Irving, CA. “Effect of Cataract Surgery on IOP in the
OHTS Observation Group”
65. OHSU/Legacy Health System Ophthalmology Grand Rounds. April 2011. Portland, OR.
“Ophthalmology Lessons from Studies in American Indian/Alaskan Natives”
66. World Glaucoma Association. July 2011. Paris, France. “Sleep Apnea and Glaucoma, Are they
related?”
67. World Glaucoma Association. Best of the American Glaucoma Society. July 2011. Paris, France.
“Effect of Cataract Surgery on IOP in the OHTS Observation Group”
68. Thorny Issues. Sept 2011. Portland, OR. “Cases in glaucoma: the good, bad, and ugly”
69. Sally Letson Conference. Sept 2011. Ottawa, Canada. “Cataract surgery: the „new‟ treatment for
glaucoma
70. Sally Letson Conference. Sept 2011. Ottawa, Canada. “Screening for breast, cervical, and prostate
cancer: Why not glaucoma”.
71. Sally Letson Conference. Sept 2011. Ottawa, Canada. “Continuous IOP monitoring: ready for
primetime?”
72. American Academy of Ophthalmology. October 2011. Orlando, FL. Glaucoma Subspecialty Day
Moderator: “Update on Structure and Function”.
73. American Academy of Ophthalmology. October 2011. Orlando, FL. Best of Anterior Segment
meetings: “Reduction in intraocular pressure after cataract extraction in The Ocular Hypertension
Treatment Study (OHTS).”
74. American Academy of Ophthalmology. October 2011. Orlando, FL. Paper session. “Change in
intraocular pressure after cataract extraction in The Ocular Hypertension Treatment Study (OHTS).”
75. American Academy of Ophthalmology. October 2011. Orlando, FL. Instruction course. “Managing
the failing bleb”.
76. American Public Health Association annual meeting. October 2011. Washington, DC. “The
comparative effectiveness of telemedicine to detect diabetic retinopathy”.
77. American Glaucoma Society. March 2012. “AGS Video Awards”. Moderator.
78. Oregon Academy of Ophthalmology. March 2012. Moderator
79. Ophthalmology Resident Day. March 2012. Calgary, Canada. “Imaging in Glaucoma” and ““Risk
factors in Glaucoma”.
80. Ophthalmology Grand Rounds. March 2012. Calgary, Canada. “Knowing you are losing the battle
with glaucoma”
81. Israel Glaucoma Today. March 2012. Tel Aviv, Israel. “Treating the failing bleb”, “Progression in
glaucoma”; “Lessons from large randomized controlled trials”; “Continuous IOP monitoring-are we
there yet?”; “Glaucoma cases”; “Ocular surface disease and glaucoma medications”.
82. Ophthalmology Grand Rounds. September 2012. Portland, OR. “Cataract surgery, the new
glaucoma surgery?”
83. Nebraska Academy of Ophthalmology. October 2012. Omaha, NE. “Cataract surgery, the new
glaucoma surgery?”, “Knowing you are losing the battle with glaucoma”,
84. American Public Health Association Annual Meeting. October 2012. San Francisco, CA. “The long-
term Comparative Effectiveness of Telemedicine for detecting Diabetic retinopathy”.
85. American Academy of Ophthalmology Annual Meeting. October 2012. Chicago, IL. “Be compliant in
recognizing poor adherence in your patient”.
86. American Academy of Ophthalmology Annual Meeting. October 2012. Chicago, IL.
“Trabeculectomy: Tips and traps lecture course”.
87. Ophthalmology Grand Rounds, Visiting Professor. November 2012. Baylor University. Houston, Tx.
“It‟s Risky not using Risk assessment when evaluating your glaucoma patients”.

13
 88. Houston Ophthalmology Society Lecture. November 2012. Houston, Tx. “Cataract surgery, the new
glaucoma surgery?”.
89. Ophthalmology Grand Rounds, Visiting Professor. November 2012. University of Texas, Houston.
“Knowing you are losing the battle with glaucoma”.
90. American Glaucoma Society, March 2013. San Francisco, CA. Moderator: “AGS Video Awards”
91. American Glaucoma Society, March 2013. San Francisco, CA. Lecturer “Staffing in the era of EMR”
Electronic Record Symposium”
92. American Society of Cataract and Refractive Surgery (ASCRS), Glaucoma Day, April 2013. San
Francisco, CA. “The case for cataract surgery as a glaucoma procedure”.
93. Optometry Grand Rounds, Veterans Hospital. May 2013. Portland, OR. “Cataract surgery: A new
treatment for glaucoma?‟.
94. Central Oregon Glaucoma Symposium. May 2013. Brasada Ranch, OR. “Ocular Hypotensive
medications: what you forgot to ask”, “Good, Bad, and Ugly glaucoma Cases”, “It‟s Risky to not
assess Risk in glaucoma”.
95. Thorny Issues, Sept 2013. Portland, OR. Moderator: “Glaucoma Cases”
96. American Academy of Ophthalmology. November 2013. The Great Debate in Glaucoma. “For
Cataract and Glaucoma Controlled on Medication, I prefer Cataract Surgery”.
97. American Academy of Ophthalmology. Didactic course. November 2013. “Trabeculectomy: How to
maximize your success”.
98. 53rd Annual Walter Wright Day: Glaucoma Management Review Course, December 2013. Toronto,
Canada. “What to do with patients with high IOP and normal visual fields”
99. 53rd Annual Walter Wright Day: Glaucoma Management Review Course, December 2013. “Phaco:
the latest treatment for glaucoma?”
100. 53rd Annual Walter Wright Day: Glaucoma Management Review Course, December 2013.
Moderator. ”Glaucoma Under Medication”.
101. 53rd Annual Walter Wright Day: Glaucoma Management Review Course, December 2013.
Moderator. ”Glaucoma Under Attack”.

OHSU/Devers Ophthalmology Residents

1. Oswald Binford, MD
2. Terry Wood, MD
3. Paul Finley, MD
4. Silvio Gurdian, MD
5. Jennifer Balentine, MD
6. Thuy Nguyen, MD
7. Dustin Herringer, MD
8. Christopher Barone, MD
9. Sandy Chen, MD
10. Christine Richards,
11. Jonathon Solomon, MD
12. Depali Rajguru, MD
13. Eric Steele, MD
14. Andrew Westfall, MD
15. Jane Gilbert, MD
16. Thomas Myers, MD
17. Rebecca Armour, MD
18. Kristi Bailey, MD
19. Matthew Giegengack, MD
20. Laurel Quinn, DO
21. Oday Alsheikh, MD
22. Rebecca Dale, MD

14
 23. Hall McGee, MD
24. Tiffany Wong, MD
25. Michael Lloyd, MD
26. Kevin Michaels, MD
27. Ricardo Santaella, MD
28. Erik Letko, MD
29. David Dance, MD
30. Lorrina Lombardi, MD
31. Amanda Richards, MD
32. Shad Saunders, MD
33. Dilsher Dhoot, MD
34. Dinelli Monson, MD
35. Michael Page, MD
36. Angela Watkins, MD
37. Rebekah Allen, MD
38. Ellen Davis, MD
39. Lani Hoag, MD
40. Naveen Rao, MD
41. Justin Wilkinson, MD
42. Alan Bengtzen, MD
43. Jack Courtney, MD
44. Jennifer Rose-Nussbaumer
45. Shandiz Tehrani, MD
46. Daniel Tu, MD
47. Blake Acohido, MD
48. Rory Allar, MD
49. Ambar Faridi, MD
50. Laura Gadzala, MD
51. Kamden Kopani, MD
52. Stephanie Kramer, MD
53. Matthew Raeker, MD
54. Seema Gupta, MD
55. Jacqueline Ng, MD
56. Manjool Shah, MD
57. Grant Aaker, MD
58. Jardine Griffin, MD
59. Anthony Grillo, MD
60. Laura Kopplin, MD
61. Benjamin Siatu‟u, MD

Glaucoma Fellows
1. Kai Goh, MD. 2003. Location: Perth, Australia
2. Christopher Engleman, MD. 2003. Location: Stanford University, Stanford, CA
3. Kevin Pikey, MD. 2003. Location: University of Kansas, Kansas City, KS
4. Annisa Jamil, MD. 2004. Location: Seattle, WA
5. Emily Patterson, MD. 2004. Location: Portland, OR
6. Rodrigo Torres, MD. 2005. Location: Palm Springs, CA
7. Hau Nguyen, MD. 2005. Location: San Jose, CA
8. Hung Pham, MD. 2007. Location: Los Angeles, CA
9. Paul McKenzie, MD, PhD. 2008. Location: Vancouver, BC. Canada
10. Zachary Hoffelt, MD. 2009. Location: Portland, OR.

15
 11. Michael Lloyd, MD. 2009. Location, Provo, UT
12. Indira Paudahal, MD. 2009. Kathmandu, Nepal.
13. Marta Pazos, MD. 2009. Barcelona, Spain
14. Christopher Shen, MD. 2010. Seattle, WA.
15. Yvonne Chu, MD. 2011. Houston, Tx.
16. Asem Alqudah, MD. 2011. King Abdullah Hospital, Ibid, Jordon
17. Robert Kinast, MD. 2011. Portland, OR
18. Hana Takasugawa, MD. 2012. Portland, OR
19. Derek Pau, MD. 2012. Jacksonville, FL
20. Helen Koenigsman, MD. 2013. Medford, OR
21. Igor Estrovich, MD. 2014. Current
22. Pui Yi Boey, MD. 2014. Current

Book Review
1. Campbell DG and Netland PA. Stereo Atlas of Glaucoma. 1st Ed. CV Mosby, 1998. J Glaucoma.
2. Tasman W and Jaeger EA. The Wills Eye Hospital Atlas of Clinical Ophthalmology. Lippincott-
Raven. 1996. J Glaucoma

Published Abstracts
1. Mansberger SL, Harris A, Arend O, etal. Small PCO2 Changes Significantly Alter Retinal Flow
Indices as Measured by the Scanning Laser Ophthalmoscope. Invest Ophthalmol Vis Sci. 1993; 34
(Suppl): 1395
2. Mansberger SL, Harris A. Acute Effect of Apraclonidine on Perimacular Hemodynamics. Invest
Ophthalmol Vis Sci. 1994; 35 (Suppl): 2176.
3. Mansberger SL, Sample PA, Weinreb RN. Short Wavelength Perimetry in Patients with Large Cups
and Normal Automated Achromatic Visual Fields. Invest Ophthalmol Vis Sci. 1998; 39 (Suppl); 491.
4. Mansberger SL, Williams JM, Sample PA, Zangwill LM, Weinreb RN. Confocal Scanning Laser
Ophthalmoscopy in Patients with Large Cup to Disc Ratios and Normal or Abnormal Functional
Testing. Invest Ophthalmol Vis Sci. 1999; 40 (Suppl); 657.
5. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment
Study (OHTS) Group: Classification of visual field abnormalities in the Ocular Hypertension
Treatment Study (OHTS). Invest Ophthalmol Vis Sci 1999;40(4):S69.
6. Keltner JL, Johnson CA, Cello KE, Quigg JM, Kass MA, Gordon MO and the OHTS group. Severity
of the types of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest
Opthalmol Vis Sci 2000;41(4):S84.
7. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular
Hypertension Treatment Study (OHTS) Group: Reproducibility of reading of optic disc cup/disc
ratio in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci
1999;40(4):S283.
8. Mansberger SL, Spry PGD, Fortune BA, Eke T, Johnson CA, Cioffi GA Cioffi. Frequency Doubling
Perimetry and the Detection of Eye Disease in the community. Invest Ophthalmol Vis Sci. 2000; 41
(Suppl): 455.
9. Johnson, CA, Spry, PGD, Cioffi, GA, Mansberger SL. Evaluation of a Variety of Visual Function
Tests in Ocular Hypertension and Early Glaucoma Patients. Invest Ophthalmol Vis Sci. 2000; 41
(Suppl): 541
10. Brandt JD, Beiser J, Kass MA, Gordon MO, for the OHTS Study Group. The relationship of corneal
thickness and IOP response to topical β-blocker in the Ocular Hypertension Treatment Study. Invest
Opthalmol Vis Sci 2001; 42(4): S421.
11. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA, Ocular
Hypertension Study Group. Visual field technician performance in the Ocular Hypertension
Treatment Study (OHTS). Invest Opthalmol Vis Sci 2001;42(4): S152.

16
12. Mansberger SL, Johnson, CA, Cioffi, GA, Krishnadas, R, Srinivasan, M, Balamurugan, V, Kim, U,
Smith, SD, Wilkins, JH, Gritz, DC. Screening for Glaucoma in India with the Frequency Doubling
Perimetry Test. Invest Ophthalmol Vis Sci. 2002; 43 (Suppl): 2154.
13. Mansberger SL, Johnson, CA, Butler, WA, Cioffi, GA. Screening with Frequency Doubling
Technology Perimetry in a Metropolitan Community. Invest Ophthalmol Vis Sci. 2003; 44 (Suppl):
3413.
14. Mansberger SL, Johnson, CA, Accuracy of Ophthalmologists for predicting glaucoma from ocular
hypertension. Invest Ophthalmol Vis Sci. 2004
15. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment Study. A
predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding
pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). Invest Ophthalmol Vis Sci
2004;45:E-Abstract 955. Presented at ARVO.
16. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular Hypertension
Treatment Study (OHTS) group. Types of visual field abnormalities that subsequently become
visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS).
Invest Ophthalmol Vis Sci 2004;45:E-Abstract 2134. Presented at ARVO.
17. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the Ocular
Hypertension Treatment Study Group. Detection and predictive value of optic disc hemorrhages in
the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 940.
Presented at ARVO.
18. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular Hypertension
Treatment Study Group. Is there an association of topical ocular hypotensive medication with lens
opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS).
Invest Ophthal Vis Sci 2005; 46: E-Abstract 2448. Presented at ARVO.
19. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW and
the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality control in the Ocular
Hypertenstion Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up
Study. Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3738. Presented at ARVO.
20. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and the Ocular
Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to topical beta-
adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular
Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 2449.
Presented at ARVO.
21. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC, Kass MA,
Gordon MO and the Ocular Hypertension Treatment Study Group. Test-retest reproducibility of
determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest
Ophthal Vis Sci 2005;46: E-Abstract 3630. Presented at ARVO.
22. Mansberger SL, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker T.
Causes of Visual Impairment and Common Eye Problems in Northwest American Indian/Alaskan
Natives. American Glaucoma Society. March 2005.
23. Mansberger SL, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker T.
Causes of Visual Impairment and Common Eye Problems in Northwest American Indian/Alaskan
Natives. National Institutes of Health. Native American Research Center for Health. November
2005.
24. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA,
Gordon MO and the OHTS CSLO Ancillary Study Group. Baseline topographic optic disc
measurements are associated with the development of primary open angle glaucoma: The Confocal
Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthal Vis Sci 46: E-Abstract
3631. Presented at ARVO May 1-6, 2005.

17
25. Mansberger SL, Fortune B, Demirel S, Zhang X, Hood DC, Patterson E, Jamil A, Cioffi GA, Johnson
CA. Comparison Between Multifocal Visual Evoked Potentials (mfVEP) and Standard Automated
Perimetry (SAP) in High-Risk Ocular Hypertension and Early Glaucoma. ARVO 2006.
26. Nguyen HT, Pikey KP, Gardiner SK, Cioffi GA, and Mansberger SL. Variability of HRT Parameters
in Contour Line Placement, With and Without the Aid of Stereographic Photographs. ARVO 2006.
27. Cioffi GA and Mansberger SL. Comparison Of the Risk Estimates For Converting To Glaucoma
With Two Published Risk Calculators. ARVO 2006.
28. McClure TM and Mansberger SL. The Effect of Visual Impairment on Vision-Related Quality of Life
in American Indian/Alaska Native Populations. ARVO 2006.
29. Mansberger SL, Cioffi GA, Choi D, Johnson CA. Screening Tests for Visually Significant Eye
Diseases in American Indian/Alaska Native Participants. ARVO 2006.
30. Brandt JD, Beiser JA, Gordon MO, Lin SC , Alexander MY, Kass MA and the Ocular Hypertension
Treatment Study Group. Time Dependent Changes in Central Corneal Thickness in the Ocular
Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2006; E-Abstract 4422. Presented
at ARVO.
31. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon MO, Beck
RW and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the
Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT).
Invest Ophthal Vis Sci 2006; E-Abstract 3394. Presented at ARVO.
32. Mansberger SL, Kass M, The OHTS Group, The EGPS Group. OHTS/EGPS: Clinical Significance
of Baseline Asymmetry in Predicting the Risk of Developing POAG. Annual Meeting of the American
Glaucoma Society. March 2007.
33. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and Ocular
Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses of Visual Field
Progression in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-
Abstract 4447. Presented at ARVO.
34. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and Ocular
Hypertension Treatment Study Group. A Comparison Of Full Threshold and Swedish Interactive
Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension Treatment Study
(OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 1643. Presented at ARVO.
35. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA,Gordon MO,and Ocular
Hypertension Treatment Study Group. The Predictive Accuracy of the One-Eyed Trial in the
Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007; E-Abstract 5555.
Presented at ARVO.
36. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension
Treatment Study Group. Phased transition from traditional data entry to a web-based system.
Presented at SCT May 21-24,2007.
37. Demirel S and the Ocular Hypertension Treatment Study Group. Rates of change of mean
deviation in the OHTS. Presented at ARVO, May 6, 2010.Mansberger SL, Nguyen H, Torres R,
Demirel S, Fortune BA, Gardiner SK, Cioffi GA, Johnson CA. Patterns of optic disc change in early
glaucoma and glaucoma suspect patients. ARVO 2007.
38. McClure TM, Swanson IL, Becker TM, Coleman AL, Cioffi GA, Mansberger SL. Changes in Vision-
Related Quality of Life in Native American/Alaska Native Populations After Best-Correction. ARVO
2007.
39. Demirel S, Fortune BA, Zhang X, Hood DC, Patterson E, Jamil A, Mansberger SL, Cioffi GA,
Johnson CA. Effect of Recording Duration on Diagnostic Performance of Multifocal Visual Evoked
Potentials in High-Risk Ocular Hypertension and Early Glaucoma. ARVO 2007.
40. Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is a history of
diabetes mellitus (DM) protective against developing primary open-angle glaucoma (POAG)?
Presented at the American Glaucoma Society, March 7, 2008.

18
41. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the Ocular Hypertension
Treatment Study Group. Application of Brusini‟s Glaucoma Staging System 2 (GSS 2) to
glaucomatous visual fields in the Ocular Hypertension Treatment Study. Presented at ARVO, April
27, 2008.
42. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and the Ocular
Hypertension Treatment Study Group. Intraocular pressure variability in observation participants in
the Ocular Hypertension Treatment Study. Presented at ARVO, April 28, 2008.
43. Kymes SM, Kass MA, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study
Group. The 20-year incidence of primary open-angle glaucoma among people with ocular
hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.
44. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the Ocular Hypertension Treatment
Study Group. Retinal vein occlusions (RVO) in the Ocular Hypertension Treatment Study.
Presented at ARVO, May 1, 2008.
45. Long EF, Dunn D, Gordon MO, the Ocular Hypertension Treatment Study group. Close-out
manual of procedures for a long-term clinical trial. Presented at the Society for Clinical Trials. May
19, 2008.
46. Gordon MO, Sarli C, Long EF, LaRue C, the Ocular Hypertension Treatment Study Group.
Assessing the impact of research. Presented at the Society for Clinical Trials, May 20, 2008.
47. Kass MA, Gordon MO, the Ocular Hypertension Treatment Study Group. Diabetes and Glaucoma.
Arch Ophthalmol. 2008;126(5):746-747.
48. Mansberger SL, Fallon S, Wong B, Lucas B. Predictive factors for following up with an eye care in
those at risk for glaucoma. American Glaucoma Society 2008
49. Mackenzie PJ, Johnson CA, Gritz DC, Krishnadas SR, Mansberger SL. Predictive Value of
Heidelberg Retinal Tomography and Frequency Doubling Technology Perimetry for Detecting
Glaucoma in a Developing Country. ARVO 2008.
50. Pham H, Gritz DC, Krishnadas SR, Johnson CA, Mansberger SL. Frequency Doubling Technology
Perimetry Repeatability in a Developing Country. ARVO 2008.
51. Demirel S, Fortune BA, Fan J, Levine RA, Torres R, Nguyen H, Mansberger SL, Gardiner SK, Cioffi
GA, Johnson CA. Predicting Progressive Glaucomatous Optic Neuropathy Using Standard
Automated Perimetry. ARVO 2008.
52. Mansberger SL, McClure TM, Swanson IL, Lambert WE, Cioffi GA. Predictive Validity of the
Glaucoma Treatment Compliance Assessment Tool. ARVO 2008.
53. O'Leary N, Mansberger SL, Twa MD, Fortune BA, Lloyd MJ, Cioffi GA, Johnson CA, Garway-Heath
DF, Crabb DP. Glaucomatous Progression in Series of Stereo-Paired Photographs and Heidelberg
Retinal Tomography Images. ARVO 2008.
54. McClure TM, Swanson IL, Lambert WE, Cioffi GA, Mansberger SL. Psychometric Properties of the
Glaucoma Treatment Compliance Assessment Tool. ARVO 2008.
55. Swanson IL, McClure TM, Cioffi GA, Lambert WE, Mansberger SL. Content Validity of a Glaucoma
Compliance Focus Group. ARVO 2008.
56. Z. Hoffelt, S.L. Mansberger, S. Fallon, B. Wong, B. Lucas. Predictive Factors for Following Up With
an Eye Care Provider in Those at Risk for Glaucoma. ARVO 2009
57. P.J. Mackenzie, H. Pham, N.G. Stouthidis, S.L. Mansberger, S.K. Gardiner, C.F. Burgoyne.
Peripapillary HRT Reflectance Changes in Non-Human Primate Experimental Glaucoma. ARVO
2009
58. T.M. McClure, I. Swanson, K. Wooten, T.M. Becker, S.L. Mansberger. Proportion of Diabetic
Retinopathy Found in Rural and Urban Populations of American Indian/Alaska Natives and Other
Ethnicities Using Either a Telemedicine Protocol or Traditional Surveillance Techniques. ARVO
2009.
59. S. Demirel, Z. Hoffelt, C.A. Johnson, S.L. Mansberger, G.A. Cioffi. Stability of Central Corneal
Thickness (cct) in Individuals With High-risk Ocular Hypertension or Early Glaucoma. ARVO 2009.

19
60. Gordon MO, Heuer DK, Higginbotham EJ, Parrish RK, Morris PA, Dunn DA, Wilson BS, Kass MA,
and the Ocular Hypertension Treatment Study Group. Impact of attributing cause of abnormality to
POAG on endpoint rate and statistical power in the OHTS. Presented at ARVO, May 2, 2010.
61. Kass MA and the Ocular Hypertension Treatment Study Group. Incidence of glaucomatous visual
field loss subsequent to initial glaucomatous optic disc deterioration in the OHTS. Presented at
ARVO, May 3, 2010.
62. Zangwill L and the Ocular Hypertension Treatment Study Group. The rate of topographic optic
disc change is faster in eyes developing POAG than in eyes not developing POAG: CSLO Ancilliary
Study to the OHTS. Presented at ARVO, May 3, 2010.
63. DeMoraes C and the Ocular Hypertension Treatment Study Group. Effect of treatment on rates of
visual field change in the OHTS. Presented at ARVO, May 3, 2010.
64. Brandt JD and the Ocular Hypertension Treatment Study Group. Does Adjusting IOP for central
corneal thickness improve accuracy of the prediction model for the development of POAG?
Presented at ARVO, May 4, 2010.
65. TM McClure, K Wooten, T. Becker, SL Mansberger, 5/2-6/2010, ARVO, Ft. Lauderdale, FL. Abstract,
Accepted: Proportion of Progression of Diabetic Eye Disease in Patients Monitored With a Non-
Mydriatic Retinal Camera
66. SL Mansberger, K Wooten, T Becker, SL Mansberger. Pacific Region Indigenous Doctor
Conference, (PriDoc). August 2010. British Columbia, Canada. “Telemedicine to detect diabetic
retinopathy in American Indian/Alaskan Natives.”
67. SL Mansberger,T Zaback, TM Becker. Using Telemedicine to Detect Diabetic Retinopathy in AI/AN
and other Ethnicities. Oregon Public Health Association Annual Conference, Corvallis, Oregon.
October 2010.
68. SL Mansberger, TM Becker. Using Telemedicine to Detect Diabetic Retinopathy in AI/AN and other
Ethnicities. American Public Health Association Annual Meeting, Denver, Colorado. November 2010.
69. SL Mansberger, MO Gordon, H Jampel, A Bhorade, JD Brandt, B Wilson, MA Kass, and the Ocular
Hypertension Treatment Study (OHTS) Group. Change in intraocular pressure after cataract
extraction in The Ocular Hypertension Treatment Study (OHTS). American Glaucoma Society, March
2011
70. SL Mansberger, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore, TM Becker. Using
Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population. Contemporary
Northwest Tribal Health Conference, Portland, Oregon. March 2011.
71. SL Mansberger, K Gleitsmann, S Gardiner, C Sheppler, D Moore, and T Becker. “Using
Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population”. Prevention Research
Conference, Atlanta, Georgia. April 2011.
72. SL Mansberger, K Gleitsmann, S Gardiner, C Sheppler, D Moore, and T Becker. “Using
Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population”. CDC Translational
conference Minneapolis, MN. April 2011.
73. A Alqudah, SL Mansberger, S Gardiner, C Blachly, S Demirel. “The association between quality of
life and visual field status in glaucoma patients.” Presented at ARVO, May 2011
74. SL Mansberger, MO Gordon, H Jampel, A Bhorade, JD Brandt, B Wilson, MA Kass, and the Ocular
Hypertension Treatment Study (OHTS) Group. Reduction in intraocular pressure after cataract
extraction in The Ocular Hypertension Treatment Study (OHTS). American Glaucoma Society, March
2011
75. CR Sheppler, SL Mansberger, CL VanAlstine, TM Becker. Compliance with Annual Diabetic Eye
Exams Survey: Pilot Study Results. Oregon Public Health Association Annual Meeting, Corvallis,
Oregon. October 2011.
76. SL Mansberger, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore, TM Becker. The
Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy in American Indians and
Alaska Natives. American Public Health Association Annual Meeting, Washington, D.C. November
2011.

20
 77. SL Mansberger, CR Sheppler, WE Lambert, J. Lapidus, SK Gardiner, TM Becker. Validity of the
Compliance with Annual Diabetic Eye Exams Survey (CADEES). Society of Behavioral Medicine
Annual Meeting, New Orleans, Louisiana. April 2012.
78. VanAlstine C, Kymes SM, StWalley D, Sheppler CR, Mansberger SL. Cost-Effectiveness of
Telemedicine Screening for Diabetic Retinopathy. Presented at ARVO, May 2012
79. Shepper CR, Lambert WE, VanAlstine CL, Mansberger SL. Compliance with Annual Diabetic Eye
Exams Survey (CADEES): Preliminary Results. Presented at ARVO, May 2012
80. Takusagawa HL, Sheppler CR, VanAlstine C, Gardiner SK, Mansberger SL. Prevalence Of
Glaucomatous Optic Neuropathy In A Telemedicine Population. Presented at ARVO, May 2012
81. SL Mansberger, CR Sheppler, CL VanAlstine, TM Becker. Using Telemedicine to Screen for
Diabetic Retinopathy in Primary Care Clinics. Native Health Research Conference, Seattle,
Washington. July 2012.
82. TM Becker, SL Mansberger, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore. The
Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy in American Indians and
Alaska Natives. Advancing Native Health and Wellness Conference, Anchorage, Alaska. August
2012.
83. SL Mansberger, CR Sheppler, CL VanAlstine, SK Gardiner, K Wooten, TM Becker. The Long-Term
Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy. American Public Health
Association 140th Annual Meeting, San Francisco, California. October 2012.
84. CR Sheppler, SL Mansberger, CL VanAlstine. Demographic and Health Belief Variables Associated
with Adherence to Annual Diabetic Eye Exams. American Public Health Association Annual Meeting,
San Francisco, California. October 2012.
85. T Zaback, WE Lambert, M Dignan, SL Mansberger, TM Becker. Summative Evaluation of a Tribal
Telemedicine Project. American Public Health Association 140th Annual Meeting, San Francisco,
California. October 2012.
86. Koenigsman H. Kammer J, Kahook M, Cook P, Mansberger SL. Glaucoma Treatment Compliance
Assessment Tool as predictive tool for medication adherence. Presented at American Glaucoma
Society Annual meeting, March 2013
87. SL Mansberger, SK Gardiner, S Demirel, TM Becker. Long-term comparative effectiveness of
telemedicine to detect diabetic retinopathy. Telehealth Alliance of Oregon Annual Meeting,
Springfield, Oregon. April 2013.
88. CR Sheppler, SL Mansberger. Qualitative analysis of implementing a telemedicine program to
provide annual diabetic retinopathy screening exams at an internal medicine clinic: Benefits, barriers,
and future directions. Telehealth Alliance of Oregon Annual Meeting, Springfield, Oregon. April 2013.
89. SL Mansberger, SK Gardiner, S Demirel, TM Becker. Long-term comparative effectiveness of
telemedicine to detect diabetic retinopathy. Association for Research in Vision and Ophthalmology,
Seattle, Washington. May 2013.
90. GT Barker, PF Cook, MY Kahook, JA Kammer, SL Mansberger. The Glaucoma Treatment
Compliance Assessment Tool (GTCAT) has an organizational structure consistent with the Health
Belief Model. The Association for Research in Vision and Ophthalmology Annual Conference,
Seattle, WA. May 2013.
91. RM Kinast, GT Barker, SH Day, SL Mansberger. Patient satisfaction within online reviews of
ophthalmologists evaluated by contextual analysis. American Academy of Ophthalmology. New
Orleans, LA. November 2013.
92. RM Kinast, GT Barker, SH Day, SL Mansberger. Online reviews of ophthalmologists compared by
subspecialty. American Society of Cataract and refractive surgery. Boston, MA. April 2014

Published Manuscripts:
1. Harris A, Caldemeyer KS, Mansberger SL, Martin BJ. Alpha-adrenergic agonists' effects on ocular
hemodynamics. J Glaucoma. 1995 Feb;4 Suppl 1:S19-23. PMID: 19920643.

21
2. Orgul S, Mansberger S, Bacon DR, Van Buskirk EM, Cioffi GA. Optic nerve vasomotor effects of
topical beta-adrenergic antagonists in rabbits. Am J Ophthalmol. 1995 Oct;120(4):441-7. PMID:
7573301.
3. Cioffi GA, Van Buskirk EM, Mansberger S, Bacon DR, Orgul S. Optic nerve vasomotor effects of
topical beta-adrenergic antagonists in rabbits: author reply [letter]. Am J Ophthalmol. 1996
Apr;121(4):456-457.
4. Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM, Lee BL, Mansberger SL, Weinreb
RN. Elevation of human intraocular pressure at night under moderate illumination. Invest Ophth.
1999; 40(10): 2439-42. PMID: 10549652.
5. Mansberger SL, Sample PA, Zangwill L, Weinreb RN. Achromatic and Short Wavelength Automated
Perimetry in Patients with Glaucomatous Large Cups. Arch Ophthalmol. 1999; 117:1473-1477.
PMID: 10565515.
6. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, Girkin CA, Weinreb RN.
Twenty-Four-Hour pattern of Intraocular pressure in the aging population. Invest Ophthalmol Vis Sci.
1999 Nov;40(12):2912-7. PMID: 10549652
7. Keltner, J.L., C.A. Johnson, et al. “Confirmation of visual field abnormalities in the Ocular Hypertension
Treatment Study, Ocular Hypertension Treatment Study Group.” Arch Ophthalmol. 2000. 118(9):
1187-94. PMID: 10980763.
8. Gordon, M.O., M.A. Kass, and the Ocular Hypertension Treatment Study (OHTS) Group. “The
Ocular hypertension Treatment Study: design and baseline description of the participants.” Arch
Ophthalmol 2000;117(5): 573-83. PMID: 10326953.
9. Mansberger SL, Cioffi GA. Eyelash Formation Secondary to Latanoprost in a Patient with Alopecia.
Arch Ophthalmol. 2000; 118: 718-719. PMID: 10815168.
10. Kwon YH, Mansberger SL, Cioffi GA. Ganglion Cell Death in Glaucoma: Mechanisms and
Neuroprotective Strategies. Ophthalmology Clinics of North America. Sept 2000; 13(3): 465-479.
11. Cioffi GA, Mansberger SL, Spry PGD, Johnson CA, Van Buskirk EM. Frequency Doubling Perimetry
and the Detection of Eye Disease in the Community. Transactions of the American Ophthalmology
Society. 2000; 98: 195-202. PMID: 11190023.
12. Brandt, J.D., J.A. Beiser, and the Ocular Hypertension Treatment Study (OHTS) Group. Central
corneal thickness in the Ocular Hypertension Treatment Study (OHTS).” Ophthalmology. 2001.
108(10): 1779-88. PMID: 11581049.
13. Mansberger SL, Passo MS, Schalock PI,Cioffi, GA. The predictive value of a one-day, one-eyed trial
on the one-month ocular hypotensive response of latanoprost 0.005%. Am J Ophthalmol. 2001;
132:869-871. PMID: 11730650
14. Mansberger SL. Management of Iris Melanoma with Secondary Glaucoma. J Glaucoma. 2002.
11:71-74.
15. Gordon, MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP,
Parrish RK 2nd, Wilson MR, Kass Ma; the Ocular Hypertension Treatment Study (OHTS) Group.
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-
angle glaucoma. Arch Ophthalmol. 2002 June;120(6):714-20; discussion 829-30. PMID: 12049575
16. Johnson, C.A., J.L. Keltner, and the Ocular Hypertension Treatment Study (OHTS) Group.
Baseline visual field characteristics in the ocular hypertension treatment study.” Ophthalmology.
2002 109(3): 432-7.
17. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson
MR, Gordon MO; the Ocular Hypertension Treatment Study Group. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or
prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13;
discussion 829-30. PMID: 12049574
18. Mansberger SL, Passo MS, Schalock PI, Cioffi GA. The predictive value of a one-day, one-eyed trial
on the one-month ocular hypotensive response of latanoprost 0.005%. Letter. Am J Ophthalmol.
2002; 134:150.

22
19. Mansberger SL. Screening in India with the Frequency Doubling Technology Perimetry test.
Masters of Public Health thesis. Oregon Health Science University Department of Public Health and
Preventive Medicine. 2002
20. Keltner, J.L., C.A. Johnson, and the Ocular Hypertension Treatment Study (OHTS) Group.
“Classification of visual field abnormalities in the ocular hypertension treatment study.” Arch
Ophthalmol. 2003 121(5): 643-50. PMID: 12742841.
21. Mansberger SL, Zangwill LM, Sample PA, Choi D, Weinreb RN. The relationship of optic disc
topography and visual function in eyes with large cup to disc ratio. Am J Ophthalmol. 2003: 136:
888-894. PMID: 14597041
22. Fortune B, Goh K, Demirel S, Novitsky K, Mansberger SL, Johnson CA and Cioffi GA: Detection of
glaucomatous visual field loss using multifocal VEP. Perimetry Update 2002/2003 (Henson and Wall,
eds), The Hague: Kugler Publications, 2004, pp 251-260.
23. Ennis FA, Blachly C, Cioffi GA, Mansberger SL and Johnson CA: The effect of contour-line drawing
criteria on optic disc parameters as measured with the HRT. Perimetry Update 2002/2003 (Henson
and Wall, eds), The Hague: Kugler Publications, 2004, pp 329-330.
24. Brandt, J.D., J.A. Beiser, and the Ocular Hypertension Treatment Study (OHTS) Group. “Central
corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular
Hypertension Treatment Study.” Am J Ophthalmol. 2004. 138(5): 717-22. PMID: 15531304.
25. Higginbotham, E.J., M.O. Gordon, and the Ocular Hypertension Treatment Study (OHTS) Group.
“The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-
angle glaucoma in African American individuals.” Arch Ophthalmol. 2004 122(6): 813-20. PMID:
15197055
26. Mansberger SL. A risk calculator to determine the probability of glaucoma. Journal of Glaucoma.
2004. 13: 345-47. PMID: 15226665.
27. Zangwill, L.M., R.N. Weinreb, and the Ocular Hypertension Treatment Study (OHTS) Group.
“Racial differences in optic disc topography: baseline results from the confocal scanning laser
ophthalmoscopy ancillary study to the ocular hypertension treatment study.” Arch Ophthalmol. 2004
122(1): 22-8. PMID: 14718290.
28. Kass MA, Gordon MO, Kymes SM; the Ocular Hypertension Treatment Study (OHTS) Group.
Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch
Ophthalmol. 2005 July;123(7):1021-2. PMID: 16009857.
29. Spry PGD, Johnson CA, Mansberger SL, Cioffi GA. Psychophysical investigation of ganglion cell
loss in early glaucoma. Journal of Glaucoma. 2005. 14(1): 11-19. PMID: 15650598.
30. Mansberger SL. Management of hypotony after needling revision of an encapsulated bleb. Journal
of Glaucoma. 2005. 14(4). 299-301.
31. Mansberger SL, Johnson CA, Cioffi GA, Choi D, Krishnadas SR, Srinavasan M, Balamurugan V,
Kim U, Smith SD, Wilkins JH, Gritz DC. Predictive Value of Frequency Doubling Technology
perimetry for detecting glaucoma in a developing country. Journal of Glaucoma. 2005. 14(2): 128-
134. PMID: 15741814.
32. Mansberger SL, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker TM.
Causes of Visual Impairment and Common Eye Problems in Northwest American Indians and
Alaskan Natives. American Journal of Public Health. 2005. 95(5): 881-6. PMID: 15855469.
33. Mansberger SL, Demeril S. Early Detection of Glaucomatous Visual Field Loss: the Why, What,
Where, and How. Clinics of North America. September 2005. 18(3):365-374. PMID: 16054994
34. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM,
Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO; the Ocular Hypertension
Treatment Study Group. Baseline topographic optic disc measurements are associated with the
development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy
Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005
Sep;123(9):1188-97. PMID: 16157798

23
35. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C,
Vandenbroucke R, Kass MA, Gordon MO, the Ocular Hypertension Treatment Group: Test-retest
Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders.
Am J Ophthalmol 2005;140:762-64. PMID:16226544.
36. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular
Hypertension Treatment Study Group (OHTS). Normal Visual Field test results following
glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study. Arch Ophthalmol
2005;123:1201-06. PMCID:1828122.
37. Mansberger SL, Patterson E. Risk Calculators: Evidence-based care of ocular hypertension and
glaucoma patients. In: Grehn F, Stamper R, editors. Glaucoma (Essentials in Ophthalmology). New
York: Springer; 2006. p. 36-46.
38. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension
Treatment Study (OHTS) Group. Management of Ocular Hypertension: A cost-Effectiveness
Approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141:997-1008.
PMCID:1775049.
39. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension
Treatment Study (OHTS) Group. Asymmetries and Visual Field Summaries as Predictors of
Glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci
2006;47:3896-3903. PMCID:1995656.
40. Keltner, J.L., C.A. Johnson, and the Ocular Hypertension Treatment Study Group. The association
between glaucomatous visual fields and optic nerve head features in Ocular Hypertension Treatment
Study.” Ophthalmology. 2006. 113(9): 1603-12. PMID: 18091452
41. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA,
and the Ocular Hypertension Treatment Study (OHTS) Group. Topical Ocular Hypotensive
Medication and Lens Opacification: Evidence from the Ocular Hypertension Treatment Study (OHTS).
Am J Ophthalmol 2006;142:800-12. PMCID:1976472.
42. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR,
Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Detection
and Prognostic Significance of Optic Disc Hemorrhages During the Ocular Hypertension Treatment
Study. Ophthalmology 2006;113:2137-43. PMCID:1995568.
43. The Ocular Hypertension Treatment Study (OHTS) Group and the European Glaucoma
Prevention Study (EGPS) Group. A Validated Prediction Model for the Development of Primary
Open-Angle Glaucoma in Individuals with Ocular Hypertension. Ophthalmology 2007;114:10-19.
PMCID:1995665.
44. Torres R, Nguyen H, Mansberger SL. Glaucoma: the sneak thief of sight. Federal Practitioner.
February 2006. 23(supplement 1): 9-15.
45. Mansberger SL. Normal-tension glaucoma in American Indians/Alaska Natives: a sheep in wolf‟s
clothing. Glaucoma Today. March/April 2006. 4(2): 12-14.
46. Mansberger SL and Cioffi GA. The Probability of Glaucoma from Ocular Hypertension determined
by Ophthalmologists in comparison to a Risk Calculator. J Glaucoma. 2006 Oct;15(5):426-31. PMID:
16988606.
47. Fortune B, Demirel S, Zhang X, Hood DC, Patterson E, Jamil A, Mansberger SL, Cioffi GA, Johnson
CA.. Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension
and early glaucoma. Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1173-80. PMID: 18414101.
48. Mansberger SL, Wilson DA. Ocular hypotony. Roy and Fraunfelder‟s Current Ocular Therapy 6th
Edition. Saunders. July 2007.
49. Netland PA, Mansberger SL, Lin S. Uncontrolled Intraocular Pressure After Endoscopic
Cyclophotocoagulation. Journal of Glaucoma. 2007 Mar;16(2):265-267. PMID: 17473744.
50. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA. Comparison
of Initial IOP Response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in

24
 African Americans and Whites in the Ocular Hypertension Treatment Study (OHTS). Archives of
Ophthalmology. Apr 2007; 125(4):454-9. PMID: 17420364.
51. Mansberger SL, Edmunds B, Johnson CA, Kent K, Cioffi GA. Community visual field screening:
prevalence of follow-up and factors associated with follow-up of participants with abnormal Frequency
Doubling Perimetry Technology results. Ophthalmic Epidemiology, 14:1-7. May-Jun 2007. PMID:
17613848.
52. Mansberger SL, Johnson CA, Cioffi GA. The results of screening frequency doubling technology
perimetry in different locations of the community. J Glaucoma. 2007 Jan;16(1):73-80. PMID:
17224754.
53. Mansberger SL, Lin S, Netland PA. “Uncontrolled Intraocular Pressure After Endoscopic
Cyclophotocoagulation.” Letter. Mar;16(2):265-7. 2007.
54. Medeiros FA, Thomas R, Mansberger SL, Gupta N, Weinreb RN, Vitale S. “Clinical Trials and
Intraocular Pressure.” In: Weinreb RN, Brandt JD, Garway-Heath DF, Medeiros FA, editors.
Intraocular pressure. The Hague, Netherlands: Kugler Publications; 2007. p. 105-20.
55. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and
the Ocular Hypertension Treatment Study (OHTS) Group. Visual Field quality control in the
Ocular Hypertenstion Treatment Study (OHTS). J Glaucoma. J Glaucoma 2007;16:665-9.
PMID:18091452.
56. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. Diabetes and
Glaucoma. Arch Ophthalmol 2008;126(5):746-a-7. PMID: 18474807.
57. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a
History of Diabetes Mellitus Protective Against Developing Primary Open-Angle Glaucoma? Arch
Ophthalmol 2008;126:280-1. PMID:18268230.
58. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension
Treatment Study Group. Changes in Central Corneal Thickness Over Time: The Ocular
Hypertension Treatment Study. Ophthalmology 2008;115:1550-1556. PMID:18378313.
59. Coleman A, Mansberger SL, Wilson R. Chapter 36: Epidemiology of Primary Open Angle
Glaucoma. Book chapter: Albert & Jakobiec‟s Principles and Practice of Ophthalmology, 3rd Edition.
Elsevier. 2008.
60. Patterson E, Ng J, Jamil A, Cioffi GA, Mansberger SL. Late-onset proptosis with Baerveldt
glaucoma implants. Br J Ophthalmol. 2008 Apr;92(4):580-2. PMID: 18055571.
61. Torres RJ, Patterson E, Edmunds B, Becker T, Cioffi GA, Mansberger SL. Central Corneal
Thickness in Northwestern American/Alaskan Natives and Comparison to White and African
Americans. Am J Ophthalmol. Nov; 146(5): 747-51. 2008. PMID: 18672219.
62. Fortune B, Zhang X, Hood DC, Demirel S, Patterson E, Jamil A, Mansberger SL, Cioffi GA, and
Johnson CA. Effect of Recording Duration on Diagnostic Performance of Multifocal Visual Evoked
Potentials in High-Risk Ocular Hypertension and Early Glaucoma. J Glaucoma. 2008 Apr-
May;17(3):175-82. PMID: 18414101.
63. Mansberger SL. “Which glaucoma medications should be used as initial therapy?” Curbside
Consultations in Glaucoma: 49 clinical questions. p135-138. Book Chapter. Editors: Heuer DK,
Gedde SJ, Lewis RA. Thorofare, NJ: SLACK, 2008:xix, 247 p..
64. Pham H, Mansberger SL, Brandt J. “Argon Laser Trabeculoplasty: Still the Gold Standard.” Argon
laser trabeculoplasty versus selective laser trabeculoplasty. Surv Ophthalmol. 2008 Nov-
Dec;53(6):641-6. PMID: 9026324.
65. Mansberger SL, Medeiros FA, Gordon M. “Diagnostic Tools for Calculation of Glaucoma Risk”.
Surv Ophthalmol. 2008 Nov;53 Suppl1:S11-6. Review. PMID: 19038619.
66. Bhorade AM, Gordon MO, Wilson B, Weinrab RN, Kass MA and the Ocular Hypertension
Treatment Study Group. Variability of Intraocular Pressure Measurements in Observation
Participants in the Ocular Hypertension Treatment Study. Ophthalmology 2009;116:717-724.
NIHMS ID:159280.

25
67. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP,
Parrish RK, Wilson MR, and the Ocular Hypertension Treatment Study (OHTS) Group. Delaying
Treatment of Ocular Hypertension. Archives of Ophthalmology 2010; 128(3):276-287. PMID:
20212196.
68. Barnett EM, Fantin A, Wilson BS, and the Ocular Hypertension Treatment Study (OHTS) Group.
The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study. Ophthalmology
2010; 117(3):484-8. PMID: 20031222.
69. Demirel S, Fortune B, Fan J, Levine RA, Torres R, Nguyen H, Mansberger SL, Gardiner SK, Cioffi
GA, Johnson CA. “Predicting progressive glaucomatous optic neuropathy using baseline standard
automated perimetry data." Invest Ophthalmol Vis Sci. 2009 Feb;50(2):674-80. PMID: 18936149.
70. Sultan MB, Mansberger SL, Lee PP. Understanding the importance of IOP variables in glaucoma: a
systematic review. Surv Ophthalmol. 2009 Nov-Dec;54(6):643-62. PMID: 19665744..
71. McClure TM, Choi D, Becker T, Cioffi GA, Mansberger SL. The effect of visual impairment on vision-
related quality of life in American Indian/Alaska Natives. Ophthalmic Epidemiol. 2009 Mar-
Apr;16(2):128-35. PMID: 19353401.
72. Brandt J, Pham H, Mansberger SL. “Argon Laser Trabeculoplasty: Still the Gold Standard.” Surv
Ophthalmol. 2009 May-Jun;54(3):428. author reply.
73. Nguyen HT, Pikey KP, Gardiner SK, Gritz D, Krishnadas D, Cioffi GA, Mansberger SL. Intraobserver
variability of confocal scanning laser ophthalmoscopy with and without stereo photographs. Br J
Ophthalmol. 2009 Nov;93(11):1552-3. PMID: 19854740.
74. Mansberger SL. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol. 2010
Jan;149(1):1-3. PMID: 20103035.
75. Mansberger SL. “Risk factors: The risk calculator” Book chapter. In: Giaconi JA, Law SK, Coleman
AL, Caprioli J, editors. Pearls of glaucoma management. Berlin: Springer; 2010. p. 191-194.
76. O'Leary N, Crabb DP, Mansberger SL, et al. Glaucomatous progression in series of stereoscopic
photographs and Heidelberg retina tomograph images. Arch Ophthalmol 2010;128:560-8. PMID:
20457976.
77. Mansberger SL. “Use Risk Assessment when treating your ocular hypertension and glaucoma
patients.” Book Chapter. Glaucoma Topics and Trends. 2010: p5-6.
78. Weinreb RN, Zangwill LM, Jain Sonia, Becerra LM, Dirkes Keri, Piltz-Seymour JR, Cioffi GA, Trick
GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA for the OHTS CLSO Ancillary
Study Group. Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy
Ancillary Study to the Ocular Hypertension Treatment Study. Ophthalmology 2010; 117(9):1674-83.
PMID:20633931.
79. Bhorade AM, Wilson BS, Gordon MO, PalmbergP, Weinreb RN, Miller E, Chang RT, Kass MA, for the
Ocular Hypertension Treatment Study Group. The Utility of the Monocular Trial: Data from the
Ocular Hypertension Treatment Study. Ophthalmology 2010;117(11):2047-54. PMID:20619460.
80. Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA, for
the Ocular Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses of
Visual Field Progression in Participants of the Ocular Hypertension Treatment Study. Arch
Ophthalmol 2010;128(12):1528-32. PMID:21149774.
81. McClure TM, Wooten K, Nield C, Becker TM, Mansberger SL. The Impact of Eyeglasses on Vision-
Related Quality of Life in American Indian/Alaska Natives. Am J Ophthalmol. 2011 Jan;151(1):175-
182. PMID: 20951973.
82. Gao F, Miller JP, XiongC, Beiser JA, Gordon MO, the Ocular Hypertension Treatment Study
(OHTS) Group. A Joint-Modeling Approach to Assess the Impact of Biomarker Variability on the Risk
of Developing Clinical Outcome. Statistical Methods & Applications. 2011;20(1):83-100.
PMID:21339862.
83. Hoffelt Z, Fallon S, Wong BA, Lucas B, Coleman AL, Mills RP, Wilson R, Mansberger SL. Glaucoma
public service announcements: factors associated with follow-up of participants with risk factors for
glaucoma. Ophthalmology. Jul;118(7):1327-33. 2011. PMID: 21439644

26
 84. Dreer LE, Girkin C, Mansberger SL. Determinants of Medication Adherence to Topical Glaucoma
Therapy. Journal of Glaucoma. 2012 Apr-May;21(4):234-40. PMID:21623223
85. Thapa SS, Paudyal I, Khanal S, Paudel N, Mansberger SL, van Rens GH. Central corneal thickness
and intraocular pressure in a Nepalese population: the Bhaktapur Glaucoma Study. J Glaucoma.
2012 Sep;21(7):481-5. PMID: 21499121.
86. Mansberger SL, MacKenzie PJ, Falardeau J. Optic disc cupping associated with neurosyphilis. J
Glaucoma. 2013 Feb;22(2):80-3. PMID: 21946555.
87. Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA; Ocular
Hypertension Treatment Study Group. Reduction in intraocular pressure after cataract extraction: the
Ocular Hypertension Treatment Study. Ophthalmology. 2012 Sep;119(9):1826-31. PMID: 22608478.
88. Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA;
Ocular Hypertension Treatment Study Group. Series length used during trend analysis affects
sensitivity to changes in progression rate in the ocular hypertension treatment study. Invest
Ophthalmol Vis Sci. 2013 Feb;54(2):1252-9. PMID 23349433.
89. Lloyd MJ, Mansberger SL, Fortune BA, Nguyen H, Torres R, Demirel S, Gardiner SK, Johnson CA,
Cioffi GA. Features of optic disc progression in patients with ocular hypertension and early glaucoma.
J Glaucoma. 2013 Jun-Jul;22(5):343-8. PMID: 23719180.
90. Koenigsman H, Mansberger SL. Choroidal Effusions. Book Chapter in Glaucoma: Medical
Diagnosis and Therapy. Editors: Shaarawy, Sherwood, Hitchings, Crowston. In Press. 2013
91. Mansberger SL. “Cataract surgery: The „New‟ glaucoma procedure” Book Chapter in Surgical
Innovations in Glaucoma. Editors: Samples and Ahmed . In Press. 2013
92. Mansberger SL, Gleitsmann K, Gardiner S, Sheppler C, Demirel S, Wooten K, Becker TM.
Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic
retinopathy screening examinations: a randomized controlled trial. Telemedicine and e-Health. In
Press. 2013.
93. Estrovich I and Mansberger SL. "Does cataract extraction produce a significant and sustained IOP
reduction? When should I perform a combined procedure versus cataract surgery alone?" Curbside
Consultation in Glaucoma: 49 Clinical Questions, second edition. Editors: Heuer, Lewis, Panarelli,
and Gedde. In Press. 2013
94. Sheppler, CR, Lambert, WE, Gardiner, SK, Becker, TM, Mansberger, SL. Predicting Adherence to
Diabetic Eye Exams: Development of the Compliance with Annual Diabetic Eye Exams Survey.
Ophthalmology (Accepted, in press).
95.

Volunteer and Community Service

1. Multnomah Play school parent teacher, 2004-2011
2. Bridlemile Soccer, coach, 2006-present
3. Goose Hollow Family Shelter, 2005-present

Hobbies/Interests
I enjoy playing and coaching soccer, biking, hiking, novels, traveling, triathlons, swimming, golf, socializing,
working in the yard, and other outside endeavors.

Family
Wife: Heather
Daughters: Katelynn, Allison, Louisa

27